Assuntos
Efeitos Psicossociais da Doença , Atenção à Saúde/métodos , Epidemia de Opioides/prevenção & controle , Transtornos Relacionados ao Uso de Opioides/terapia , Atenção à Saúde/tendências , Overdose de Drogas/diagnóstico , Overdose de Drogas/mortalidade , Overdose de Drogas/prevenção & controle , Humanos , Epidemia de Opioides/mortalidade , Epidemia de Opioides/tendências , Transtornos Relacionados ao Uso de Opioides/diagnóstico , Transtornos Relacionados ao Uso de Opioides/mortalidade , Sociedades Médicas/tendênciasRESUMO
Academic medical centers (AMCs) are presently facing enormous challenges arising from a prospective decline in government funding for research and education, shifting payment models emphasizing efficiency and value, and increasing competition. Left unabated, these challenges will drive many AMCs to de-emphasize or forsake their core missions in an effort to survive. Stemming from a symposium held at the 2015 Scientific Sessions of the American College of Cardiology titled, "The Academic Medical Center of the Future," we propose a series of changes, including internal restructuring, system-wide partnership, and novel approaches to support research and education, that are designed to better position AMCs to compete and face their growing challenges in a manner that preserves their essential missions. In aggregate, these changes will facilitate establishing the academic medical system of the future.
Assuntos
Centros Médicos Acadêmicos/economia , Cardiologia/educação , Atenção à Saúde/organização & administração , Educação de Pós-Graduação em Medicina/organização & administração , Reforma dos Serviços de Saúde , Humanos , Estados UnidosAssuntos
Comitês Consultivos/normas , American Heart Association , Cardiologia/normas , Fundações/normas , Doença Arterial Periférica/terapia , Guias de Prática Clínica como Assunto/normas , Gerenciamento Clínico , Humanos , Doença Arterial Periférica/diagnóstico , Doença Arterial Periférica/epidemiologia , Relatório de Pesquisa/normas , Estados Unidos/epidemiologiaAssuntos
Infarto do Miocárdio/terapia , Reperfusão Miocárdica/métodos , Intervenção Coronária Percutânea , Medição de Risco , Terapia Trombolítica , American Heart Association , Cardiologia/métodos , Cardiologia/normas , Protocolos Clínicos/classificação , Protocolos Clínicos/normas , Técnicas de Diagnóstico Cardiovascular , Gerenciamento Clínico , Eletrocardiografia , Serviços Médicos de Emergência/métodos , Serviços Médicos de Emergência/organização & administração , Medicina Baseada em Evidências/métodos , Medicina Baseada em Evidências/normas , Humanos , Conduta do Tratamento Medicamentoso/normas , Infarto do Miocárdio/diagnóstico , Infarto do Miocárdio/epidemiologia , Seleção de Pacientes , Estados UnidosRESUMO
STUDY OBJECTIVE: To assess whether the increased risk of ibutilide-induced torsade de pointes in patients with heart failure may be due to increased ibutilide exposure, we sought to determine if the pharmacokinetics of ibutilide are altered in patients with heart failure due to left ventricular systolic dysfunction. DESIGN: Multicenter, prospective pharmacokinetic study. SETTING: Four academic medical centers in the United States. PATIENTS: Sixteen adult patients with atrial fibrillation or atrial flutter requiring conversion to normal sinus rhythm: six patients who had New York Heart Association (NYHA) class II or III heart failure due to left ventricular dysfunction (mean +/- SD left ventricular ejection fraction [LVEF] 30 +/- 9%); 10 patients who did not have left ventricular dysfunction (mean +/- SD LVEF 54 +/- 5% in six of these 10 patients) served as controls. INTERVENTION: All patients received a single dose of ibutilide 1.0 mg administered intravenously over 10 minutes. Blood samples were obtained through an indwelling catheter in the contralateral arm before ibutilide administration, at the end of the infusion, and at 5, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours after the infusion. MEASUREMENTS AND MAIN RESULTS: Serum ibutilide concentrations were determined by using high-performance liquid chromatography and mass spectrometry. No significant differences were noted between the heart failure and normal left ventricular function groups in the following parameters: maximum serum ibutilide concentration (median [interquartile range] 3.8 [2.3-5.7] vs 5.8 [3.1-14.4] microg/L, p=0.31), area under the serum concentration-time curve from time zero extrapolated to infinity (mean +/- SD 11.0 +/- 9.4 vs 13.2 +/- 10.6 microg*hr/L, p=0.88), steady-state volume of distribution (1380 +/- 334 vs 1390 +/- 964 L, p=0.99), systemic clearance (129 +/- 60 vs 125 +/- 81 L/hr, p=0.92), or half-life (12.5 +/- 10.7 vs 12.4 +/- 8.6 hrs, p=0.99). CONCLUSION: The pharmacokinetics of ibutilide do not appear to be altered in patients with NYHA class II or III heart failure due to left ventricular systolic dysfunction. Therefore, the increased risk of ibutilide-induced torsade de pointes in patients with heart failure does not appear to be due to increased ibutilide exposure.